Opthea Completes Final Patient Visit for COAST Trial
Ticker: OPTEY · Form: 6-K · Filed: Feb 18, 2025 · CIK: 1815620
Sentiment: bullish
Topics: clinical-trial-completion, biotech, drug-development, amd
TL;DR
Opthea just finished its final patient visit for the COAST trial, moving closer to potential drug approval.
AI Summary
Opthea Limited announced on February 18, 2025, that it has completed the final patient visit for Week 52 in its COAST Phase 3 clinical trial. This trial is evaluating the efficacy and safety of its drug candidate, sofpruvant (OPT-302), for the treatment of wet age-related macular degeneration (AMD). The completion of this milestone is a significant step towards potential regulatory submissions.
Why It Matters
The completion of the Week 52 patient visit in the COAST trial is a crucial step for Opthea, bringing them closer to potentially seeking regulatory approval for sofpruvant in treating wet AMD.
Risk Assessment
Risk Level: medium — Clinical trial completion is positive, but regulatory approval and market success are not guaranteed.
Key Numbers
- Week 52 — Final Patient Visit (Indicates completion of the primary data collection phase for the COAST trial.)
Key Players & Entities
- Opthea Limited (company) — Registrant
- COAST (trial) — Phase 3 clinical trial
- sofpruvant (OPT-302) (drug) — Drug candidate being tested
- wet age-related macular degeneration (AMD) (disease) — Condition being treated
- February 18, 2025 (date) — Date of filing and announcement
- Week 52 (milestone) — Final patient visit point
FAQ
What is the primary purpose of the COAST trial?
The COAST trial is a Phase 3 clinical trial evaluating the efficacy and safety of sofpruvant (OPT-302) for the treatment of wet age-related macular degeneration (AMD).
What specific milestone did Opthea announce?
Opthea announced the completion of the final patient visit for Week 52 in its COAST Phase 3 clinical trial.
What is the drug candidate being tested in the COAST trial?
The drug candidate being tested is sofpruvant, also known as OPT-302.
What condition is sofpruvant intended to treat?
Sofpruvant is intended to treat wet age-related macular degeneration (AMD).
When was this report filed with the SEC?
This report (Form 6-K) was filed with the SEC on February 18, 2025.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on February 18, 2025 regarding Opthea Ltd (OPTEY).